Skip to content
Search
Please enter at least 3 characters.

Latest Stories

One in three people in UK miss work due to delays in accessing NHS care: Savanta poll

One in three people in UK miss work due to delays in accessing NHS care: Savanta poll

 Young adults aged 18 to 34 years were worst affected, more than half this working population were forced to miss work as they pursued or waited for NHS care

Long waiting times for National Health Service (NHS) care are leaving people too sick to work in the UK, which is affecting the country’s economy.


One in three people missed work in 2022 due to delays in accessing NHS care, revealed a new survey by Pollsters Savanta.

The market research consultancy surveyed 2,235 people in the UK this month on behalf of the Liberal Democrats.

According to the survey results, 19 per cent of the participants could not go to work as they were waiting for a GP appointment.

While 15 per cent of the respondents had to take a long period off work while they waited for treatment or surgery, 12 per cent missed work as they waited for emergency dental treatments.

Overall, 36 per cent of those surveyed had missed at least some work because of difficulty getting NHS care.

Sarah Olney, a Liberal Democrat Treasury spokesperson, has expressed strong disappointment that so many patients have been left to suffer “as a result of this Conservative government’s neglect.”

“[Rishi] Sunak and [Jeremy] Hunt’s failure to get a grip on the crisis in our NHS is having a detrimental effect on the entire country. Millions battling health conditions have been left in limbo and our economy is suffering as a result,” Olney told The Guardian.

The Savanta poll found that more than half (54 per cent) of young adults aged 18 to 34 years have been forced to miss work while they pursued or waited for care, such as an appointment with a family doctor.

More people out of work because of long-term sickness

Last year, Office for National Statistics (ONS) revealed that around 2.5 million people in the UK were out of the labour force between June and August 2022 because of “long-term sickness.”

The number of working-age adults who were economically inactive because of long-term sickness were around 2.0 million people in spring 2019.

Since the COVID-19 pandemic hit the UK in early 2020, the number of people out of work because of long-term sickness has risen by 363,000, it stated.

Mental health, musculoskeletal conditions and heart disease were some of the main causes of long-term sickness or disability.

According to the ONS, the industries that saw the highest levels of long-term sickness rates were wholesale and retail, transport and storage, accommodation and food service, and health and social sector.

It cited a range of factors behind this recent rise in economic inactivity, including National Health Service (NHS) waiting times, long COVID, and the ageing workforce.

It is estimated that over 9 million people across the UK are waiting for hospital care, mostly in England (almost 7.8 million).

Back to Work Plan  

Chancellor Jeremy Hunt and Secretary of State for Work and Pensions, Mel Stride recently unveiled a “Back to Work Plan” to get more people into work.

It aims to help up to 1,100,000 people with long-term health conditions, disabilities or long-term unemployment to look for and stay in work.

To execute the plan, the government is investing £2.5 billion over the next five years - including over £300m of additional investment next year

It will be built on the £7 billion package announced at this year’s Spring Budget, which included investment targeted at services for mental health, musculoskeletal conditions and cardiovascular disease.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less